Top-News
Pharmazeutika USA

Lexicon Pharmaceuticals Inc News

Aktie
WKN:  A14SSK ISIN:  US5288723027 US-Symbol:  LXRX
1,649 €
-0,049 €
-2,89%
17.05.24 17:14:09
Handeln Depot/Watchlist
Aktienanzahl *
244,92 Mio.
Marktkapitalisierung *
398,85 Mio. €
Streubesitz
-
Index-Zugehörigkeit
Nasdaq Composite Index
IR-Website
zur Website
*Stand: 26.02.2024

Lexicon Pharmaceuticals Inc News

13.03.24 - PR Newswire
Thinking about buying stock in Lexicon Pharmaceuticals, Cassava Sciences, Clearside Biomedical, Lantern Pharma, or ATAI Life Sciences?
Thinking about buying stock in Lexicon Pharmaceuticals, Cassava Sciences, Clearside Biomedical, Lantern Pharma, or ATAI Life Sciences? PR Newswire
13.10.23 - PR Newswire
Thinking about buying stock in Comtech Telecommunications, Tantech Holdings, MDxHealth, Lexicon Pharmaceuticals, or micromobility.com?
Thinking about buying stock in Comtech Telecommunications, Tantech Holdings, MDxHealth, Lexicon Pharmaceuticals, or micromobility.com? PR Newswire
10.10.23 - PR Newswire
Thinking about buying stock in Immunic, BioXcel Therapeutics, Coherent Corp, Emx Royalty, or Lexicon Pharmaceuticals?
Thinking about buying stock in Immunic, BioXcel Therapeutics, Coherent Corp, Emx Royalty, or Lexicon Pharmaceuticals? PR Newswire
01.07.22 - PR Newswire
Thinking about buying stock in Cytokinetics, Pure Storage, Revlon, Lexicon Pharmaceuticals, or Bloom Energy?
Thinking about buying stock in Cytokinetics, Pure Storage, Revlon, Lexicon Pharmaceuticals, or Bloom Energy? PR Newswire
26.03.22 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lexicon Pharmaceuticals, Inc. - LXRX
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lexicon Pharmaceuticals, Inc. - LXRX PR Newswire
02.03.22 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lexicon Pharmaceuticals, Inc. - LXRX
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lexicon Pharmaceuticals, Inc. - LXRX PR Newswire
31.12.21 - PR Newswire
Thinking about buying stock in Assertio Holdings, Siyata Mobile, Insignia Systems, Energy Focus, or Lexicon Pharmaceuticals?
Thinking about buying stock in Assertio Holdings, Siyata Mobile, Insignia Systems, Energy Focus, or Lexicon Pharmaceuticals? PR Newswire
30.08.21 - PR Newswire
Thinking about buying stock in Marqeta, Lexicon Pharmaceuticals, Kala Pharmaceuticals, Owlet, or New Oriental Education?
Thinking about buying stock in Marqeta, Lexicon Pharmaceuticals, Kala Pharmaceuticals, Owlet, or New Oriental Education? PR Newswire
30.07.21 - PR Newswire
Thinking about buying stock in Lexicon Pharmaceuticals, Agile Therapeutics, Summit Wireless, Resonant, or Nokia?
Thinking about buying stock in Lexicon Pharmaceuticals, Agile Therapeutics, Summit Wireless, Resonant, or Nokia? PR Newswire
08.12.20 - PR Newswire
Thinking about buying stock in Pfizer, Nio, Lexicon Pharmaceuticals, Oncolytics Biotech, or Boeing?
Thinking about buying stock in Pfizer, Nio, Lexicon Pharmaceuticals, Oncolytics Biotech, or Boeing? PR Newswire
03.08.20 - PR Newswire
GTCR and TerSera Therapeutics Announce Acquisition of Xermelo
GTCR and TerSera Therapeutics Announce Acquisition of Xermelo Acquisition Further Expands TerSera's Portfolio in Oncology PR Newswire
21.07.20 - PR Newswire
Thinking about buying stock in New Age Beverages, Lexicon Pharmaceuticals, Miragen Therapeutics, Opko Health, or Niu Technologies?
Thinking about buying stock in New Age Beverages, Lexicon Pharmaceuticals, Miragen Therapeutics, Opko Health, or Niu Technologies? PR Newswire
26.02.19 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - LXRX
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming ...
14.02.19 - PR Newswire
Lifshitz & Miller LLP Announces Investigation of Arlo Technologies, Inc., Alkermes Public Limited Company, Lexicon Pharmaceuticals, Inc., BSB Bancorp, Inc., Markel Corporation, Natural Health Trends Corp., and Nova Lifestyle, Inc.
Lifshitz & Miller LLP Announces Investigation of Arlo Technologies, Inc., Alkermes Public Limited Company, Lexicon Pharmaceuticals, Inc., BSB Bancorp, Inc., Markel Corporation, ...
30.01.19 - PR Newswire
LEXICON INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm
LEXICON INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm ...
22.01.19 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lexicon Pharmaceuticals, Inc. - LXRX
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lexicon Pharmaceuticals, Inc. - LXRX PR Newswire
26.07.18 - PR Newswire
New Insights Revealed in National Survey Show More Advances Are Needed for the Type 1 Diabetes Community
New Insights Revealed in National Survey Show More Advances Are Needed for the Type 1 Diabetes Community Endocrinologists and Adults with Type 1 Diabetes Struggle to Keep ...
22.05.18 - PR Newswire
FDA to review Zynquista™ (sotagliflozin) as potential treatment for type 1 diabetes
FDA to review Zynquista™ (sotagliflozin) as potential treatment for type 1 diabetes PR Newswire
08.11.17 - PR Newswire
Lexicon Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides A Business Update
Lexicon Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides A Business Update XERMELO® (telotristat ethyl) U.S. Quarterly Net Sales Reach $5.3 Million ...
03.11.17 - PR Newswire
Lexicon Pharmaceuticals To Host Third Quarter 2017 Financial Results Conference Call And Webcast On November 8, 2017
Lexicon Pharmaceuticals To Host Third Quarter 2017 Financial Results Conference Call And Webcast On November 8, 2017 PR Newswire

Newssuche

Videos

newspaper
17.05.24 +14,15%
Technical Trading: Gold Long-​Chance
Gold Long Typ: Turbo Open End WKN: VD1G7Y Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »